Topic resource collection
Approved comparison material connected to this topic.
479 resourcesRead both sides
| Peptide | Primary Aging Target | Mechanism of Action | Clinical Evidence Strength | Typical Cycle Duration | Maintenance Requirement | Professional Assessment ||—|—|—|—|—|—|| Thymalin | Immune senescence | Restores thymic epith…
The table below compares the three most researched peptides for autoimmune conditions by mechanism, receptor target, disease applicability, and typical research dosing protocols. Each peptide intervenes at a different immune cont…
The table below summarizes key peptide candidates, their primary mechanism, typical research dosing ranges, and evidence quality. This comparison is for educational reference. Dosing decisions in human fertility protocols require…
Before selecting peptides for neuropathy research protocols, understanding which biological pathways each compound targets determines experimental design and outcome measures. The table below compares five leading research peptid…
Thymalin Thymic immune restoration via T-cell differentiation Moderate. Soviet longitudinal cohorts, modern replication limited 10mg daily × 10 days, quarterly cycles CD4+ T-cell count +22%, IL-6 reduction Strongest immune senesc…
| Peptide | Primary Mechanism | Glutathione Impact | Autophagy Effect | Mitochondrial Function | Evidence Level | Professional Assessment ||—|—|—|—|—|—|| BPC-157 | Upregulates antioxidant enzyme expression (SOD, catalase, GPx) | …
| Peptide | Primary Mechanism | Tissue Target | Standard Research Dose | Administration Frequency | Key Advantage | Bottom Line ||—|—|—|—|—|—|| TB-500 (Thymosin Beta-4) | Upregulates actin, promotes angiogenesis and cell migratio…
Semaglutide GLP-1 receptor agonist. Delays gastric emptying, suppresses ghrelin, reduces dopamine reward signaling 5–7 days; weekly subcutaneous injection STEP-1 trial: 47% reduction in dessert intake frequency, 38% reduction in …
The table below summarises mechanism, optimal timing, and evidence quality for the five peptides ranked above. Bottom-line assessments reflect real-world applicability based on current research. Not theoretical potential. BPC-157…
BPC-157 VEGF upregulation, angiogenesis, fibroblast proliferation 250–500 mcg/day Inflammatory + Early Proliferative (Days 1–14) Once or twice daily subcutaneous First-line peptide for acute soft tissue injuries. Strongest eviden…
Tirzepatide Dual GIP/GLP-1 agonist ~5 days Weekly Moderate (via insulin sensitivity) Very High Moderate positive (via nutrient partitioning) Best overall for multi-pathway maintenance. Highest regain prevention rate in clinical t…
Before selecting a peptide for glucose regulation research, match the mechanism to the pathway you're investigating. This table ranks peptides by primary mechanism, glucose-lowering magnitude, and receptor specificity. Tirzepatid…
| Peptide | Primary Mechanism | Optimal Phase | Typical Dose Range (Research) | Evidence Strength | Recovery Time Reduction | Professional Assessment ||—|—|—|—|—|—|| BPC-157 | VEGF stabilization, angiogenesis promotion | Prolifer…
Most surgical recovery protocols use two peptides concurrently during the acute phase, then taper to one during remodeling. The logic: BPC-157 and TB-500 target non-overlapping mechanisms during proliferation, so stacking them co…
BPC-157 Upregulates VEGF, FGF-2; promotes angiogenesis and collagen synthesis Local injury site (gastrocnemius, soleus) 250–500mcg Daily (subcutaneous or IM near injury) Inflammatory + Proliferative (days 1–21) First-line choice …
Before selecting a peptide for plateau intervention, understand how each class addresses the specific mechanisms driving metabolic adaptation. This table ranks peptides by their primary mechanism, clinical evidence strength, and …
MK 677 GH secretagogue. IGF-1 elevation, lipolysis 8–12% Once daily Strong. Multiple Phase 2 trials Most reliable metabolic amplifier with reproducible IGF-1 response GHRP-2 GH secretagogue. Pulsatile GH release 6–10% 1–2× daily …
The critical distinction most peptide discussions miss is this: growth hormone pathways improve bone density globally by shifting the remodeling balance across the entire skeleton. Healing peptides improve bone structure locally …
BPC-157 Upregulates VEGF and bFGF; enhances angiogenesis and fibroblast migration via FAK-paxillin pathway 250–500mcg daily Daily (subcutaneous or oral) Broad soft tissue repair; gastric protective origin means high GI tolerance …
MK-677 (Ibutamoren) Oral GH secretagogue → sustained IGF-1 elevation 3.2–5.1% lumbar spine over 18 months (meta-analysis, JCEM 2019) 10–20 mg oral daily 12–16 weeks for measurable BMD change Best systemic option for patients who …